Table 2.
Parameter | Calcitriol Users
|
Matched Controls
|
Crude RR (95% CI) | ||||
---|---|---|---|---|---|---|---|
n | Events | Rate (95% CI) | n | Events | Rate (95% CI) | ||
All study patients | 429 | 109 | 12.8 (10.4 to 15.2) | 989 | 299 | 18.3 (15.2 to 21.4) | 0.70 (0.56 to 0.87) |
Age (yr) | |||||||
<65 | 164 | 32 | 8.4 (5.5 to 11.3) | 315 | 76 | 11.6 (7.6 to 15.6) | 0.73 (0.48 to 1.09) |
65 to 75 | 139 | 38 | 13.4 (9.1 to 17.6) | 336 | 102 | 19.3 (13.7 to 24.8) | 0.69 (0.48 to 0.99) |
>75 | 126 | 39 | 20.8 (14.3 to 27.3) | 338 | 121 | 26.2 (19.2 to 33.2) | 0.79 (0.56 to 1.14) |
Diabetes | |||||||
yes | 276 | 65 | 12.5 (9.4 to 15.5) | 581 | 197 | 21.4 (16.9 to 25.9) | 0.58 (0.44 to 0.77) |
no | 153 | 44 | 13.3 (9.4 to 17.3) | 408 | 102 | 14.3 (10.1 to 18.5) | 0.93 (0.65 to 1.33) |
eGFR (ml/min per 1.73 m2) | |||||||
15 to 30 | 249 | 77 | 14.1 (10.9 to 17.2) | 495 | 204 | 21.9 (17.5 to 26.4) | 0.64 (0.49 to 0.84) |
30 to 60 | 180 | 32 | 10.5 (6.9 to 14.1) | 494 | 95 | 13.1 (8.9 to 17.2) | 0.80 (0.54 to 1.20) |
PTH (pg/ml) | |||||||
70 to 150 | 117 | 16 | 8.6 (4.4 to 12.9) | 675 | 150 | 15.4 (11.6 to 19.2) | 0.56 (0.34 to 0.93) |
150 to 300 | 224 | 52 | 11.3 (8.2 to 14.3) | 253 | 116 | 22.0 (16.0 to 28.0) | 0.51 (0.37 to 0.72) |
>300 | 88 | 41 | 20.0 (13.9 to 26.1) | 61 | 33 | 23.9 (11.7 to 36.0) | 0.84 (0.53 to 1.32) |
RR, relative risk.